Back
Viatris Inc. (VTRS)
PharmaceuticalsVTRS · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$16.66
−1.77%Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for education and research only — not financial advice.
Key metrics
EPS
$-3.00
ROE
-2.0%
Gross margin
39.8%
Debt/Equity
1.00x
Revenue growth
8.1%
Viatris Inc. — company intelligence
Earnings surprises
Q1 2026$0.59 vs $0.51 est+15.2%
Q4 2025$0.57 vs $0.54 est+4.8%
Q3 2025$0.67 vs $0.63 est+5.8%
Q2 2025$0.62 vs $0.57 est+9.4%
Insider activity · 90 days
2 buys3 sellsnet -64,025 shares
Groothuis Leo FransBuy 2,756 · Jun 30, 2026
SIMMONS DAVID SBuy 2,362 · Jun 30, 2026
Campbell PaulSell 50,076 · Jun 25, 2026
Recent SEC filings
4 — Insider transaction reportJul 1, 2026
4 — Insider transaction reportJul 1, 2026
8-K — Material event reportJul 1, 2026
Latest news
3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now — Yahoo · 3d ago
Should Viatris’ Japan IgA Nephropathy Win and New Loan Shape VTRS Investors’ Next Move? — Yahoo · 5d ago
Viatris (VTRS) Secures Loan Amid Positive Phase 3 Results — Yahoo · 5d ago
Viatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Now — Yahoo · 5d ago
Viatris (VTRS) is a Great Momentum Stock: Should You Buy? — Yahoo · 1w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
About Viatris Inc.
Weekly undervalued picks (like VTRS)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.